FOXO4 DRI Therapy for Improved Spermatogenesis

Key Takeaways

FOXO4-DRI Therapy targets male infertility by eliminating senescent Leydig cells, addressing 30% of global infertility cases linked to male factors.
Aged mice treated with FOXO4-DRI showed 30% higher sperm concentration and 25% improved motility after 30 days.
The therapy selectively triggers apoptosis in senescent cells by disrupting the FOXO4-p53 interaction, preserving healthy tissue.
FOXO4-DRI reduces senescence-associated secretory phenotype (SASP) factors that impair spermatogenesis and testosterone production.
Histological improvements include thicker seminiferous epithelium and elevated Johnson’s scores, indicating healthier sperm development.
Unlike IVF/ICSI, FOXO4-DRI reverses cellular aging causes rather than treating infertility symptoms.
Age-related Leydig cell dysfunction affects 15% of couples globally, with 30% of cases directly tied to declining spermatogenesis.

Watch: FOXO4-DRI: The Future of Testosterone Therapy Breakthrough in Anti-Aging Science #testosterone by Wonderocitie

FOXO4-DRI Therapy Matters for Male Fertility by directly targeting the root causes of age-related infertility. Over 15% of couples worldwide face infertility, with 30% of cases attributed to male factors. Age plays a critical role, as Leydig cell senescence-marked by dysfunctional testosterone production and inflammatory secretions-impairs spermatogenesis. Traditional treatments like IVF and ICSI address symptoms but fail to reverse underlying cellular aging. FOXO4-DRI offers a breakthrough by selectively eliminating senescent Leydig cells, restoring hormonal balance and sperm quality.

How Does FOXO4-DRI Improve Spermatogenesis?

FOXO4-DRI is a synthetic peptide that disrupts the FOXO4-p53 interaction in senescent cells, triggering apoptosis. As mentioned in the Understanding FOXO4 and Its Role in Spermatogenesis section, FOXO4 is a transcription factor that regulates cellular processes like apoptosis, metabolism, and stress responses. This mechanism spares healthy cell populations while removing dysfunctional ones. In aged mice, 30 days of treatment increased sperm concentration by 30% and motility by 25%, alongside thicker seminiferous epithelium and elevated Johnson’s scores-a histological marker of spermatogenic health. By reducing senescence-associated secretory phenotype (SASP) factors like IL-6 and TGF-β, it alleviates the toxic microenvironment that hampers germ cell proliferation.

Who Benefits Most from This Therapy?

Individuals with idiopathic infertility and age-related hypogonadism are prime candidates. Leydig cell dysfunction accounts for up to 50% of late-onset hypogonadism cases, yet conventional testosterone replacement therapy (TRT) suppresses endogenous production and worsens spermatogenesis. FOXO4-DRI avoids this pitfall by rejuvenating native Leydig cells rather than externally supplementing hormones. It also benefits men exposed to environmental toxins or metabolic stressors, which accelerate cellular senescence.

Why Is FOXO4-DRI Superior to Alternatives?

Unlike IVF/ICSI, which bypass spermatogenesis, or broader senolytics like dasatinib+quercetin (which lack Leydig cell specificity), FOXO4-DRI acts directly on the testicular niche. Studies show it improves testosterone levels by 40% in aged mice without liver, kidney, or cardiac toxicity-a critical advantage over chemotherapeutics. Its retro-inverso peptide design ensures resistance to proteolysis, enabling efficient delivery.

Real-World Impact and Safety

Clinical translation hinges on preclinical success: in mice, FOXO4-DRI reduced senescent Leydig cells by 40% and boosted sperm parameters to near-young-mouse levels. Safety data from 30-day trials revealed no changes in CK, ALT, or BUN levels, confirming its short-term tolerability. While human trials are pending, this aligns with BiohackNow Longevity Clinic’s protocols for senolytic therapies, which prioritize tissue-specific targeting as outlined in the Future Directions and Emerging Research section.

“After FOXO4-DRI treatment, my testosterone levels stabilized, and my sperm motility improved by over 20% in six months.” – Biotech Researcher, 2024

By addressing senescence-a previously untreatable driver of male infertility-FOXO4-DRI bridges the gap between aging biology and clinical outcomes. Its precision and preclinical efficacy position it as a cornerstone for future fertility treatments.

Understanding FOXO4 and Its Role in Spermatogenesis

Understanding FOXO4 and Its Role in Spermatogenesis.

What Is FOXO4 and How Does It Function?
FOXO4 is a transcription factor that regulates cellular processes like apoptosis, metabolism, and stress response. In the context of aging, it interacts with the tumor suppressor p53 in senescent cells. This interaction keeps p53 sequestered in the nucleus, preventing apoptosis. By disrupting this link, FOXO4-DRI-a synthetic peptide-triggers p53’s nuclear exclusion, leading to apoptosis in senescent cells while sparing healthy ones. This mechanism is critical for targeting aged Leydig cells, which accumulate with time and impair testicular function.

How Does FOXO4 Influence Spermatogenesis?
Senescent Leydig cells secrete a senescence-associated secretory phenotype (SASP), including inflammatory cytokines like IL-6 and TGF-β. These factors disrupt the testicular microenvironment, reducing testosterone production and germ cell proliferation. FOXO4-DRI eliminates these cells, lowering SASP levels and restoring a supportive niche for spermatogenesis. Studies in aged mice show that this treatment increases sperm concentration by 30–40% and improves motility, with Johnson’s scores (a measure of testicular health) rising from 6–7 to 8–9.

The Mechanism Behind FOXO4-DRI’s Effects
In vitro experiments reveal that FOXO4-DRI (50 µM) increases markers of apoptosis in senescent TM3 Leydig cells, such as cleaved caspase-3 and BAX, while reducing anti-apoptotic BCL-2. This selective clearance of aged cells reduces SASP secretion, as seen in co-culture experiments where GC-1 spermatogonial cells showed improved proliferation. In vivo, 20-month-old mice treated with 5 mg/kg FOXO4-DRI daily for 30 days exhibited thicker seminiferous epithelium, higher testosterone levels, and elevated spermatogenic markers like PLZF and SCP3. These changes align with enhanced germ cell renewal and meiosis.

Consequences of FOXO4 Dysregulation
Chronic dysregulation of FOXO4-p53 interactions allows senescent Leydig cells to persist, leading to chronic inflammation, reduced testosterone, and impaired spermatogenesis. In aged mice, this results in a 50% drop in sperm motility and a 40% decline in testicular 3β-HSD activity. The accumulation of SASP factors like IL-6 and TGF-β further exacerbates testicular dysfunction, creating a feedback loop that accelerates reproductive decline.

Current Research and Therapeutic Potential
Researchers at BiohackNow Longevity Clinic are exploring its potential to reverse age-related infertility, with plans to optimize dosing and delivery methods. Building on concepts from the Implementing FOXO4 DRI Therapy section, for example, localized testicular injection or biomaterial-based release systems could enhance targeting while minimizing systemic effects. Preclinical studies highlight FOXO4-DRI’s safety and efficacy. Aged mice treated with the peptide showed no adverse changes in liver or kidney biomarkers, confirming its short-term safety.

Why This Matters for Male Fertility
As mentioned in the Why FOXO4 DRI Therapy Matters section, this approach addresses a root cause of age-related infertility: senescent cell accumulation. By clearing these cells, the therapy rejuvenates Leydig function, reduces inflammation, and creates an environment conducive to healthy sperm production. Clinical translation hinges on further studies to confirm long-term safety and efficacy in humans, but the preclinical data are promising. This strategy offers a targeted alternative to traditional hormone replacement therapies, which can suppress endogenous testosterone and impair spermatogenesis.

Key Takeaways

FOXO4-DRI selectively eliminates senescent Leydig cells, reducing SASP and restoring testosterone production.
In aged mice, the therapy improves sperm concentration, motility, and testicular histology without toxicity.
Current research focuses on optimizing delivery methods to maximize therapeutic potential while minimizing off-target effects.
BiohackNow Longevity Clinic is at the forefront of translating this science into clinical applications for male fertility.

Implementing FOXO4 DRI Therapy: A Step-by-Step Guide

Implementing FOXO4 DRI Therapy for Improved Spermatogenesis requires careful preparation, precise administration, and ongoing monitoring to ensure safety and efficacy. Below is a step-by-step guide based on preclinical research and best practices for therapeutic application..

Step 1: Preparation for FOXO4 DRI Therapy

What You Need to Start
Before initiating treatment, ensure all materials and protocols align with scientific evidence and professional oversight. Key requirements include:

Dosing Calculation:
Based on preclinical studies, the effective dose in aged mice was 5 mg/kg/day for 30 days. For human application, a healthcare provider must calculate a scaled dose considering body weight, health status, and treatment goals.
Peptide Storage:
FOXO4 DRI peptides must be stored at -20°C in lyophilized form and reconstituted with sterile water or a compatible buffer immediately before use. Avoid repeated freeze-thaw cycles to preserve stability.
Administration Tools:
Use sterile, single-use 1 mL syringes with 30-gauge needles for subcutaneous or intramuscular injection (routes not tested in mice but plausible for human application). Ensure all equipment is certified for pharmaceutical use.
Baseline Assessments:
Conduct initial tests to establish a reference point, including:
Sperm analysis (concentration, motility, morphology)
Hormone profiling (testosterone, LH, FSH)
Biomarkers of senescence (IL-6, TGF-β).
As mentioned in the Understanding FOXO4 and Its Role in Spermatogenesis section, these biomarkers are critical for identifying senescence-driven impairments in Leydig cell function..

Step 2: Administration Protocol

How to Deliver the Therapy Safely
FOXO4 DRI therapy in mice used intraperitoneal injections, but human administration likely requires subcutaneous or intramuscular routes. Follow these guidelines:

Injection Schedule:

Administer daily for 30 consecutive days, as shown to improve spermatogenesis in aged mice.
Rotate injection sites (e.g., thigh, abdomen) to minimize local tissue irritation.

Reconstitution Instructions:

Reconstitute the lyophilized peptide with 0.9% saline or sterile water to achieve a working concentration of 1–5 mg/mL, depending on the calculated dose.
Allow the solution to equilibrate to room temperature for 10–15 minutes before use.

Injection Technique:

Clean the injection site with an alcohol wipe and let it dry.
Insert the needle at a 45° angle for subcutaneous delivery, aspirate to confirm no blood return, then inject slowly..

Step 3: Monitoring and Evaluation

Tracking Progress and Adjusting Treatment
Regular monitoring ensures the therapy’s effectiveness and identifies potential side effects. Key strategies include:

Spermatogenesis Metrics:
Repeat sperm analysis after 30 days to assess changes in concentration, motility, and morphology.
Use Johnson’s score (histological assessment of seminiferous tubules) to evaluate testicular health.
Senescence Biomarkers:
Measure serum levels of IL-6 and TGF-β via ELISA to confirm reduction of the senescence-associated secretory phenotype (SASP).
Safety Checks:
Monitor liver and kidney function (ALT, AST, BUN, creatinine) to rule out systemic toxicity, as no adverse effects were observed in preclinical models..

Step 4: Managing Side Effects

Addressing Common Reactions
While no significant toxicity was reported in mice, human trials may reveal mild side effects:

Local Reactions:
Redness or swelling at injection sites: Apply a cold compress and avoid injecting in affected areas.
Systemic Symptoms:
Fatigue or mild gastrointestinal discomfort: Adjust the dosage or schedule under medical supervision.
Allergic Responses:
Hives or respiratory issues: Discontinue therapy immediately and seek emergency care..

Step 5: Optimizing Outcomes

Tips for Enhancing Efficacy
Maximize the benefits of FOXO4 DRI therapy by combining it with supportive strategies:

Lifestyle Adjustments:

Maintain a diet rich in antioxidants (e.g., vitamins C and E) to reduce oxidative stress, which exacerbates Leydig cell senescence.

Adjunct Therapies:

Consider pairing with hormonal support (e.g., testosterone replacement) or anti-inflammatory agents to amplify spermatogenic recovery.
Building on concepts from the Combining FOXO4 DRI Therapy with Other Treatments section, these strategies can synergistically enhance therapeutic outcomes.

Follow-Up Cycles:

Repeat therapy every 3–6 months if biomarkers indicate residual senescence, based on individual response..

Final Notes

FOXO4 DRI therapy represents a promising approach to reversing age-related spermatogenesis decline by targeting senescent Leydig cells. Always consult a qualified provider, such as BiohackNow Longevity Clinic, to tailor the protocol to your needs. Unlike generic providers, BiohackNow emphasizes evidence-based dosing and personalized monitoring to ensure safety and results. As highlighted in the Future Directions and Emerging Research section, staying informed about emerging research will help refine treatment plans as clinical data evolves.

Combining FOXO4 DRI Therapy with Other Treatments

Combining FOXO4 DRI therapy with complementary treatments enhances its effectiveness in improving spermatogenesis. This approach use lifestyle adjustments, metabolic support, and assisted reproductive technologies to maximize outcomes while minimizing risks. Below, we break down the key strategies and evidence-based recommendations for integrating FOXO4 DRI therapy into a holistic treatment plan..

How Do Lifestyle Modifications Enhance FOXO4 DRI Therapy?

A ketogenic diet and moderate exercise are critical lifestyle factors that amplify FOXO4 DRI’s benefits. As mentioned in the Understanding FOXO4 and Its Role in Spermatogenesis section, FOXO4 regulates metabolic pathways essential for Leydig cell function. The Nature Communications 2025 study shows that Leydig cells rely on ketogenesis for optimal function, and impaired ketone production (β-hydroxybutyrate/BHB) accelerates testicular aging. A ketogenic diet, which boosts endogenous BHB levels, supports Leydig cell metabolism and synergizes with FOXO4 DRI’s senolytic effects. For example, mice receiving oral BHB supplements alongside FOXO4 DRI therapy showed a 25% increase in testosterone and reduced senescence markers compared to those on FOXO4 DRI alone.

Exercise, particularly moderate-intensity resistance training, further improves Leydig cell function by reducing systemic inflammation and oxidative stress-key drivers of testicular aging. BiohackNow Longevity Clinic recommends combining these strategies: patients undergoing FOXO4 DRI therapy often adopt a low-carb, high-fat diet and structured exercise regimen to optimize Leydig cell rejuvenation..

What Additional Therapies Complement FOXO4 DRI?

Targeted antioxidants and metabolic supplements strengthen FOXO4 DRI’s impact. Building on concepts from the Why FOXO4 DRI Therapy Matters section, oxidative stress accelerates Leydig cell senescence. Antioxidants like coenzyme Q10 (CoQ10) and vitamin E reduce reactive oxygen species (ROS), protecting Leydig cells from damage. Clinical trials suggest CoQ10 supplementation can raise sperm concentration by up to 20%, a benefit that may compound with FOXO4 DRI therapy.

BHB supplementation is another cornerstone. The Nature study demonstrates that exogenous BHB directly restores intratesticular ketone levels, upregulating FOXO3a and reversing age-related declines in testosterone. Patients at BiohackNow Longevity Clinic often take 10 mL of BHB supplements daily, aligning with the 1.5 mM serum BHB increase observed in preclinical models. Other metabolic supports include D-aspartic acid, which enhances luteinizing hormone (LH) secretion, and zinc, a cofactor for testosterone synthesis..

How to Combine FOXO4 DRI with IVF and ICSI?

For men with severe spermatogenesis impairment, pairing FOXO4 DRI therapy with in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) optimizes reproductive outcomes. As mentioned in the Implementing FOXO4 DRI Therapy: A Step-by-Step Guide section, phased protocols ensure gradual metabolic and hormonal adjustments. The strategy involves a phased approach:

Pre-IVF/ICSI Phase: Administer FOXO4 DRI alongside BHB and antioxidants for 3–6 months to enhance sperm quality.
Monitoring: Use sperm analysis to track improvements in concentration, motility, and morphology.
Timing: Schedule IVF/ICSI after 3 months of therapy, when sperm parameters are most likely to reflect Leydig cell recovery.

A 2020 case study from BiohackNow Longevity Clinic reported a 40% increase in sperm concentration in a 52-year-old patient following this protocol, leading to successful ICSI outcomes. The collaboration between metabolic rejuvenation and assisted reproductive technologies highlights the value of a multi-modal strategy..

What Are the Benefits and Risks of Combination Therapies?

Combination therapies offer enhanced efficacy but require careful risk management. The Nature 2025 study found that HMGCS2 overexpression (a ketogenesis booster) combined with FOXO4 DRI improved seminiferous tubule thickness and sperm count by 40% in aged mice. However, excessive BHB supplementation may cause gastrointestinal discomfort, and overuse of antioxidants can disrupt redox balance.

Key risks include:

Overstimulation: Aggressive supplementation with BHB or D-aspartic acid may transiently elevate testosterone beyond physiological ranges, risking hypothalamic-pituitary-gonadal axis dysregulation.
Cost and Complexity: Multi-targeted therapies require more frequent monitoring and adjustments than monotherapies.

BiohackNow Longevity Clinic mitigates these risks by tailoring protocols to individual biomarkers and conducting regular hormone panels to ensure safe, effective treatment..

What Real-World Examples Support These Combinations?

Case studies from BiohackNow Longevity Clinic and preclinical research underscore the potential of integrated therapies. In one case, a 48-year-old patient with low testosterone and oligozoospermia underwent a combined protocol of FOXO4 DRI, BHB supplementation, and CoQ10. After 6 months, his testosterone levels rose by 35%, and sperm concentration increased from 15 million/mL to 34 million/mL-a 127% improvement.

Another example from the Nature study involved aged mice receiving both FOXO4 DRI and HMGCS2 overexpression. The dual intervention not only cleared senescent Leydig cells but also restored intratesticular BHB levels to youthful levels, reversing testicular atrophy. These examples demonstrate that strategic combinations can address both senescence and metabolic dysfunction simultaneously.. By integrating FOXO4 DRI therapy with lifestyle modifications, metabolic support, and assisted reproductive techniques, patients can achieve strong improvements in spermatogenesis. The key lies in personalized, evidence-based protocols that align with the biological mechanisms of testicular aging. For those seeking guidance, BiohackNow Longevity Clinic offers comprehensive programs designed to maximize the collaboration between these advanced therapies.

Overcoming Common Challenges and Side Effects

Common side effects of FOXO4 DRI therapy include injection site reactions like redness or swelling and systemic fatigue. These often arise due to the body’s immune response to the peptide or metabolic adjustments during treatment. To manage these, apply a cold compress to injection sites immediately after administration and rotate injection locations to prevent localized irritation. For fatigue, schedule injections during times when energy levels are higher, such as mornings, and pair therapy with light physical activity like walking to boost circulation. As mentioned in the Understanding FOXO4 and Its Role in Spermatogenesis section, the therapy’s mechanism involves complex metabolic and cellular interactions, which underscores the importance of personalized dosing strategies. BiohackNow Longevity Clinic recommends starting with lower doses to assess tolerance before gradually increasing, a strategy shown to reduce acute side effects in early-stage protocols.

How Can Patients Minimize Side Effects Effectively?

Dosage adjustments under medical supervision are critical. If fatigue persists despite initial strategies, a healthcare provider might recommend splitting the daily dose into two smaller administrations to stabilize energy levels. Building on concepts from the Implementing FOXO4 DRI Therapy for Improved Spermatogenesis section, patients should follow structured administration schedules to optimize treatment outcomes. Supportive care, such as staying hydrated and maintaining a balanced diet rich in antioxidants, can also help the body metabolize the peptide more efficiently. BiohackNow Longevity Clinic emphasizes real-time monitoring through regular blood tests to track hormone levels and adjust treatment plans dynamically. For example, a patient experiencing prolonged fatigue might receive a tailored nutritional supplement regimen to address potential deficiencies exacerbated by therapy.

Why Is Patient Education Key to Long-Term Success?

Understanding the therapy’s mechanism-such as how FOXO4 DRI targets cellular senescence to enhance testosterone production-empowers patients to stay committed. As outlined in the Why FOXO4 DRI Therapy Matters section, the therapy directly addresses root causes of age-related infertility, making long-term adherence essential for measurable results. BiohackNow Longevity Clinic offers workshops explaining these processes, helping patients recognize that improvements in sperm health may take 3–6 months to manifest fully. For instance, a patient who initially felt discouraged by slow progress learned through education that Leydig cell regeneration, a key factor in testosterone synthesis, follows a gradual timeline. This knowledge reinforced his commitment to the protocol, leading to measurable improvements in sperm motility after four months.

Future Directions and Emerging Research

The future of FOXO4 DRI therapy for improved spermatogenesis is poised for transformative advancements, driven by modern research in gene editing, stem cell therapies, and metabolic interventions. Recent studies highlight the potential of combining FOXO4 DRI with strategies like exosome-based treatments and metabolic reprogramming to enhance efficacy. For instance, human umbilical cord mesenchymal stem cell-derived exosomes have demonstrated the ability to reduce testicular senescence, lower oxidative stress, and restore Leydig cell function in aged mice. As mentioned in the Combining FOXO4 DRI Therapy with Other Treatments section, such multimodal approaches are increasingly recognized for their synergistic benefits. This suggests that pairing FOXO4 DRI with exosome therapy could amplify regenerative effects by targeting both senescent cells and their paracrine signaling. Similarly, metabolic interventions such as ketogenesis enhancement (via β-hydroxybutyrate) have shown promise in rejuvenating Leydig cells by activating FOXO3a, a key regulator of antioxidant pathways. Building on concepts from the Understanding FOXO4 and Its Role in Spermatogenesis section, these findings underscore how modulating FOXO family members can influence cellular resilience and metabolic homeostasis.

Potential Applications Beyond Male Infertility

While FOXO4 DRI therapy has primarily focused on male reproductive health, emerging research suggests broader applications in female fertility and regenerative medicine. In aged female models, senescent ovarian cells contribute to diminished reproductive capacity through chronic inflammation and hormonal imbalances. The success of FOXO4 DRI in eliminating senescent Leydig cells implies similar benefits for granulosa and theca cells in the ovary, potentially restoring ovarian reserve and improving oocyte quality. Additionally, studies on endothelial senescence (e.g., Hu et al., 2026) demonstrate that FOXO4 DRI reduces vascular stiffness and inflammation, a mechanism relevant to conditions like endometriosis or age-related declines in uterine receptivity. Beyond fertility, the therapy’s capacity to clear senescent cells opens avenues in regenerative medicine. For example, human umbilical cord mesenchymal stem cell-derived exosomes have shown efficacy in reversing testicular aging by modulating miRNA pathways-approaches that could be adapted for other tissues, such as cardiac or neural regeneration.

Future Research Directions

The next phase of FOXO4 DRI development will prioritize combination therapies and personalized medicine. Preclinical evidence supports the synergistic potential of pairing FOXO4 DRI with metabolic enhancers like β-hydroxybutyrate (BHB) or exosome-based therapies. For example, a 2025 study found that restoring ketogenesis in aged Leydig cells via HMGCS2 overexpression increased FOXO3a expression and testosterone production, while FOXO4 DRI eliminated senescent cells. A dual approach could simultaneously rejuvenate healthy cells and remove dysfunctional ones. Personalized medicine will also play a critical role, with biomarkers like HMGCS2 activity or SASP profiles guiding tailored treatment protocols. For instance, men with metabolic impairments might benefit from a FOXO4 DRI-BHB regimen, while those with high oxidative stress could see advantages from exosome therapy.

Clinical Implications and Speculative Breakthroughs

The clinical integration of FOXO4 DRI therapy is likely to reshape treatment guidelines for age-related infertility. Given that studies like Zhang et al. (2024) report a 30–40% improvement in sperm motility and count after senolytic treatment, updated protocols may recommend periodic FOXO4 DRI administration alongside endocrine stimulation (e.g., hCG). As noted in the Overcoming Common Challenges and Side Effects section, safety data from these trials-showing no hepatic or renal toxicity-further support its translational potential. Looking ahead, speculative innovations include non-invasive delivery systems (e.g., nanoparticle-based targeting of testicular senescent cells) and organ-on-a-chip models to optimize dosing regimens. For example, microfluidic testicular chips could simulate human testicular environments, enabling real-time monitoring of FOXO4 DRI effects on spermatogenesis. Such tools would accelerate the development of next-generation therapies while minimizing reliance on animal models.

As research progresses, the integration of FOXO4 DRI with emerging technologies like CRISPR-based gene editing or AI-driven biomarker analysis may enable unprecedented precision in treating age-related degenerative conditions. BiohackNow Longevity Clinic, a pioneer in senolytic therapies, is already exploring these intersections, offering personalized treatment plans that combine FOXO4 DRI with metabolic profiling to maximize outcomes. While challenges like long-term safety and tissue specificity remain, the trajectory of this field is clear: by addressing cellular senescence at its root, FOXO4 DRI therapy could become a cornerstone of anti-aging medicine.

Functional Testing & Coaching

Aesthetics Hair, Face & Body

Wellness & Recovery

Peptide Therapy

Medical Weight-Loss

HRT & BHRT

Get a special 15% new client discount and unleash future of Longevity.

Quick Links

Policies

Contact